Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / BYSI - Akero Continues Efruxifermin Trial And Other News: The Good Bad And Ugly Of Biopharma

BYSI - Akero Continues Efruxifermin Trial And Other News: The Good Bad And Ugly Of Biopharma

BeyondSpring Inc.
  • Akero Therapeutics to continue with mid stage Efruxifermin trial.
  • BioMarin initiated mid stage study for BMN 307.
  • BeyondSpring presents positive data for Plinabulin in preventing neutropenia.

For further details see:

Akero Continues Efruxifermin Trial, And Other News: The Good, Bad And Ugly Of Biopharma
Stock Information
Company Name: BeyondSpring Inc.
Stock Symbol: BYSI
Market: NASDAQ
Website: beyondspringpharma.com
Menu
BYSI BYSI Quote BYSI Short BYSI News BYSI Articles BYSI Message Board
Get BYSI Alerts

News, Short Squeeze, Breakout and More Instantly...